Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02311855 · ClinicalTrials.gov registry record · Phase 4

Duration of Immune Response to Influenza Vaccination in Patients With RA

A Phase 4 study, sponsored by Bassett Healthcare.

Completed
Registry status
Phase 4
Development phase
87
Enrollment target

NCT02311855 is a Phase 4 study that has completed, run by Bassett Healthcare. The registered enrollment target is 87 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02311855, a Phase 4 study, has completed, sponsored by Bassett Healthcare.

COMPLETED
Registry status
Phase 4
Development phase
87 participants
Enrollment target

Study Summary

The main objective is to evaluate the strength and duration of immune response after influenza vaccination in patients with Rheumatoid Arthritis (RA) receiving treatment with biological agents as compared to a group healthy controls who do not have RA. Influenza vaccine titers will be drawn 3 times: at Baseline(prior to vaccination), 4-6 weeks post vaccination, and 5-6 months post vaccination. Influenza vaccination will be done at the baseline visit after the baseline blood draw.

Interventions

  • BIOLOGICAL Influenza vaccine

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2014-08
Est. Completion 2016-02
Phase Phase 4

Sponsor

Bassett Healthcare

16 total trials

What the Registry Record Tells You About NCT02311855

The ClinicalTrials.gov registry entry for NCT02311855 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bassett Healthcare, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Influenza vaccine is the first listed.

NCT02311855 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02311855 about?

NCT02311855 is a clinical study titled "Duration of Immune Response to Influenza Vaccination in Patients With RA". The main objective is to evaluate the strength and duration of immune response after influenza vaccination in patients with Rheumatoid Arthritis (RA) receiving treatment with biological agents as compared to a group healthy controls who do not have RA. Influenza vaccine titers will be drawn 3 times:...

What is the current status of trial NCT02311855?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 87 participants. The study started on 2014-08. Estimated completion is 2016-02.

What interventions are being tested in trial NCT02311855?

The interventions under investigation include: Influenza vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT02311855?

This trial is sponsored by Bassett Healthcare, which has 16 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.